Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 26.70
- Piotroski Score 3.00
- Grade N/A
- Symbol (GYRE)
- Company Gyre Therapeutics, Inc.
- Price $12.78
- Changes Percentage (0.16%)
- Change $0.02
- Day Low $12.47
- Day High $12.94
- Year High $30.40
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 01/13/2023
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-92,933,000
Income Statement
Quarterly
Annual
Latest News of GYRE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)
Gyre Therapeutics' intrinsic value is estimated using a Discounted Cash Flow (DCF) model, showing it's currently trading around fair value. The analysis considers future cash flows and discount rates,...
By Yahoo! Finance | 3 months ago
